RSS   Newsletter   Contact   Advertise with us
Post Online Media

Agios Pharmaceuticals chairman Marc Tessier-Lavigne to resign

Marc Tessier LavigneAgios Pharmaceuticals announced that Marc Tessier-Lavigne decided to resign as a member of the board, chairman, and as chairman of the science and technology committee.
Upon his resignation, Dr. Tessier-Lavigne will join the Company’s scientific advisory board.

Dr. Tessier-Lavigne has served as a member of Company's board since September 2011. He has served as president of the Rockefeller University, as well as professor and head of the Laboratory of Brain Development and Repair, since 2011.

On September 1, 2016, Dr. Tessier-Lavigne will assume the role of president at Stanford University.

Prior to his appointment at Rockefeller, he was employed at Genentech from 2003 to 2011, where he became executive vice president for research and chief scientific officer.

Prior to his tenure at Genentech, Dr. Tessier-Lavigne was an investigator with the Howard Hughes Medical Institute from 1994 to 2003 and a professor at Stanford University and the University of California, San Francisco from 1991 to 2003.

He is a member of the Board of Directors of Pfizer and Regeneron Pharmaceuticals.

Dr. Tessier-Lavigne is a member of the National Academy of Sciences and its Institute of Medicine, and a fellow of the Royal Society (UK), the Royal Society of Canada, the American Academy of Arts and Sciences, the American Association for the Advancement of Science, and the Academy of Medical Sciences (UK).

Dr. Tessier-Lavigne earned undergraduate degrees from McGill University and from Oxford University, where he was a Rhodes Scholar.

He received his Ph.D. from University College London, and conducted postdoctoral work at the MRC Developmental Neurobiology Unit in London and at Columbia University.

 

 LATEST MOVES FROM Massachusetts 


 
 

POST Online Media does not use cookies to collect information about visitors.   OK, hide this message   Third party ads may be using cookies, you can see how here.